![Innovent](https://pharmashots.com/public/default-image/default-730x400.png )
Innovent Reports Data from the P-III (DREAMS-1) Study of Mazdutide to Treat Type 2 Diabetes in Chinese Patients
Shots:
- The P-III (DREAMS-1) study assessed mazdutide (4mg, 6mg) vs PBO to treat T2D Chinese patients (n=320) with insufficient glycemic control for 24wks. after which, PBO group was switched to 6mg for another 24wks. NDA to the NMPA is planned for the same
- Study, at 24wks., showed reduced HbA1c of 1.57% & 2.15% vs 0.14% that sustained till 48wks.; no. of patients attaining HbA1c<7.0%, wt. reduction ≥5% plus dual targets (HbA1c<7% & wt. reduction ≥5%) were more in mazdutide group
- Furthermore, wt. loss of 9.6% at wk.48 was seen with 6mg. Reduction in cardiovascular metabolic indicators such as postprandial blood glucose, waist circumference, blood pressure, blood lipids, transaminases & urinary albumin-to-creatinine ratio were also observed
Ref: Innovent | Image: Innovent
Related News:- Innovent Biologics Reports the P-III Trial Results of Mazdutide for Treating Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
![](https://pharmashots.com/public/images/Disha-2023-03-21-64199f99761c8.png)
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.